新型抗2型糖尿病药物钠-葡萄糖协同转运蛋白2抑制剂研究进展

摘要

Sodium-glucose co-transporters(SGLT) are a family of glucose transporter found in the intestinal mucosa of the small intestine(SGLTl) and the proximal tubule of the nephron(SGLTl and SGLT2). The sodium-glucose co-transporter-2(SGLT2) is a low-affinity transporter that is specifically expressed in kidney and plays a very important role in renal glucose reabsorption in the proximal tubule. Selective inhibition of SGLT2 is an innovative therapeutic strategy for the treatment of type 2 diabetes by enhancing glucose loss through urine. In this paper, the latest research progress on SGLT2 inhibitors for the treatment of type 2 diabetes was introduced. We emphasized the mechanism of SGLT2 inhibitors, the data of biological activities and clinical trials of some SGLT2 inhibitors under research and development%钠-葡萄糖协同转运蛋白(SGLT)是一类位于小肠黏膜(SGLT1)和肾近曲小管(SGLT2和SGLT1)中的葡萄糖转运基因家族.其中,SGLT2是一种低亲和力的转运蛋白,在肾脏中特异性表达并且在近曲小管葡萄糖重吸收中发挥非常重要的作用.它可以选择性地抑制SGLT2,即可通过增加尿糖的排出来治疗2型糖尿病,是一种创造性的治疗策略.本文介绍了SGLT2抑制剂在2型糖尿病治疗研究方面的最新进展,重点综述了SGLT2抑制剂的作用机制、部分在研SGLT2抑制剂的生物活性数据及临床试验结果.